Chronic GVHD risk factors of the study population
| . | PBSC (n = 48) . | BM (n = 53) . | P . |
|---|---|---|---|
| Sex, no. (%) | |||
| Male with male donor | 11 (23) | 14 (26) | NS |
| Male with female donor | 15 (31) | 13 (25) | |
| Female with female donor | 11 (23) | 9 (17) | |
| Female with male donor | 11 (23) | 17 (32) | |
| Diagnosis, no. (%) | |||
| Acute myeloid leukemia | 25 (52) | 20 (38) | NS |
| Acute lymphoblastic leukemia | 6 (13) | 13 (24) | |
| Chronic myeloid leukemia | 17 (35) | 20 (38) | |
| Disease status, no. (%) | |||
| Chronic phase or first complete remission | 45 (94) | 50 (94) | NS |
| Advanced disease | 3 (6) | 3 (6) | |
| Cytomegalovirus status, no. (%) | |||
| Seronegative with seronegative donor | 18 (38) | 18 (34) | NS |
| Other combinations | 30 (62) | 35 (66) | |
| Patient/donor ABO mismatch, no. (%) | 13 (27) | 11 (21) | NS |
| Conditioning regimen, no. (%) | |||
| Cytoxan + total-body irradiation | 34 (71) | 39 (74) | NS |
| Cytoxan + busulfan | 9 (19) | 6 (11) | |
| Other | 5 (10) | 8 (15) | |
| Acute GVHD (%) | |||
| No. assessable for aGVHD (%) | 47 (98) | 52 (98) | NS |
| Grade | |||
| 0 | 14 (30) | 19 (37) | |
| I | 12 (25) | 11 (21) | |
| II-IV | 21 (45) | 22 (42) |
| . | PBSC (n = 48) . | BM (n = 53) . | P . |
|---|---|---|---|
| Sex, no. (%) | |||
| Male with male donor | 11 (23) | 14 (26) | NS |
| Male with female donor | 15 (31) | 13 (25) | |
| Female with female donor | 11 (23) | 9 (17) | |
| Female with male donor | 11 (23) | 17 (32) | |
| Diagnosis, no. (%) | |||
| Acute myeloid leukemia | 25 (52) | 20 (38) | NS |
| Acute lymphoblastic leukemia | 6 (13) | 13 (24) | |
| Chronic myeloid leukemia | 17 (35) | 20 (38) | |
| Disease status, no. (%) | |||
| Chronic phase or first complete remission | 45 (94) | 50 (94) | NS |
| Advanced disease | 3 (6) | 3 (6) | |
| Cytomegalovirus status, no. (%) | |||
| Seronegative with seronegative donor | 18 (38) | 18 (34) | NS |
| Other combinations | 30 (62) | 35 (66) | |
| Patient/donor ABO mismatch, no. (%) | 13 (27) | 11 (21) | NS |
| Conditioning regimen, no. (%) | |||
| Cytoxan + total-body irradiation | 34 (71) | 39 (74) | NS |
| Cytoxan + busulfan | 9 (19) | 6 (11) | |
| Other | 5 (10) | 8 (15) | |
| Acute GVHD (%) | |||
| No. assessable for aGVHD (%) | 47 (98) | 52 (98) | NS |
| Grade | |||
| 0 | 14 (30) | 19 (37) | |
| I | 12 (25) | 11 (21) | |
| II-IV | 21 (45) | 22 (42) |
NS indicates not significant.